|
Category:antidandruff, antimicrobial agents
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Assay: | 95.00 to 100.00
|
| Food Chemicals Codex Listed: | No |
| Boiling Point: | 447.51 °C. @ 760.00 mm Hg (est)
|
| Flash Point: | 323.00 °F. TCC ( 161.70 °C. ) (est)
|
| logP (o/w): | -0.136 (est) |
| Soluble in: |
| | water, 87.11 mg/L @ 25 °C (est) |
Organoleptic Properties:
| Odor and/or flavor descriptions from others (if found). |
Cosmetic Information:
Suppliers:
Safety Information:
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
intraperitoneal-guinea pig LD50 5500 ug/kg
Experientia. Vol. 44, Pg. 611, 1988.
intravenous-guinea pig LD50 7 mg/kg
Experientia. Vol. 44, Pg. 611, 1988.
intraperitoneal-mouse LD50 160 mg/kg
"CRC Handbook of Antibiotic Compounds," Vols.1- , Berdy, J., Boca Raton, FL, CRC Press, 1980Vol. 6, Pg. 63, 1981.
intravenous-mouse LD50 > 100 mg/kg
Experientia. Vol. 44, Pg. 611, 1988.
intravenous-rat LD50 > 200 mg/kg
Experientia. Vol. 44, Pg. 611, 1988.
|
| Dermal Toxicity: |
skin-guinea pig LD50 200 ug/kg
BEHAVIORAL: EXCITEMENT
BEHAVIORAL: IRRITABILITY
BEHAVIORAL: FLUID INTAKE
Experientia. Vol. 44, Pg. 611, 1988.
|
| Inhalation Toxicity: |
|
Not determined
|
Safety in Use Information:
| Category: | | antidandruff, antimicrobial agents |
| Recommendation for ovalicin usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for ovalicin flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
| EPI System: View |
| AIDS Citations:Search |
| Cancer Citations:Search |
| Toxicology Citations:Search |
| EPA ACToR:Toxicology Data |
| EPA Substance Registry Services (SRS):Registry |
| Laboratory Chemical Safety Summary :29739 |
| National Institute of Allergy and Infectious Diseases:Data |
| 7-hydroxy-8-methoxy-7-[2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-4-oxaspiro[2.5]octan-2-one |
| Chemidplus:0019683988 |
References:
| | 7-hydroxy-8-methoxy-7-[2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-4-oxaspiro[2.5]octan-2-one |
| NIST Chemistry WebBook: | Search Inchi |
| Pubchem (cid): | 29739 |
| Pubchem (sid): | 134992397 |
Other Information:
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| (1S,2R,3S,4R,5S)-(-)-4-(1,2- | epoxy-1,5-dimethyl-4-hexenyl)-4-hydroxy-5-methoxy-1-oxaspiro(2,5)octan-6-one | | | graphinone | | 7- | hydroxy-8-methoxy-7-[2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-4-oxaspiro[2.5]octan-2-one | | 1-oxa | spiro(2,5)octan-6-one, 4-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-4-hydroxy-5-methoxy-, (1S,2R,3S,4R,5S)-(-)- |
Articles:
| PubMed:Polyketides from the littoral plant associated fungus Pseudallescheria boydii. |
| PubMed:Ovalicin ameliorates compound 48/80-induced atopic dermatitis-related symptoms. |
| PubMed:Syntheses of fumagillin and ovalicin. |
| PubMed:In vivo activity of cationic immune stimulating complexes (PLUSCOMs). |
| PubMed:Total syntheses of (+/-)-ovalicin, C4(S *)-isomer, and its C5-analogs and anti-trypanosomal activities. |
| PubMed:A Diels-Alder approach to (-)-ovalicin. |
| PubMed:New bioactive sesquiterpenes from Ripartites metrodii and R. tricholoma. |
| PubMed:Structure of the angiogenesis inhibitor ovalicin bound to its noncognate target, human Type 1 methionine aminopeptidase. |
| PubMed:Antimicrosporidial activities of fumagillin, TNP-470, ovalicin, and ovalicin derivatives in vitro and in vivo. |
| PubMed:Methionine aminopeptidase 2 and cancer. |
| PubMed:Concise enantio- and diastereoselective total syntheses of fumagillol, RK-805, FR65814, ovalicin, and 5-demethylovalicin. |
| PubMed:Synthesis of ovalicin starting from D-mannose. |
| PubMed:Structural basis for the functional differences between type I and type II human methionine aminopeptidases. |
| PubMed:Investigations into microsporidian methionine aminopeptidase type 2: a therapeutic target for microsporidiosis. |
| PubMed:Synthesis and biological evaluation of novel fumagillin and ovalicin analogues. |
| PubMed:A single amino acid residue defines the difference in ovalicin sensitivity between type I and II methionine aminopeptidases. |
| PubMed:Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation. |
| PubMed:Fumagalone, a reversible inhibitor of type 2 methionine aminopeptidase and angiogenesis. |
| PubMed:Methionine aminopeptidase 2 is a new target for the metastasis-associated protein, S100A4. |
| PubMed:QSAR of the inhibition of angiogenesis by TNP-470 and ovalicin analogues: another example of an allosteric interaction. |
| PubMed:Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. |
| PubMed:Structure and function of the methionine aminopeptidases. |
| PubMed:Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells. |
| PubMed:Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. |
| PubMed:Mer-f3, 12-hydroxy-ovalicin, produced by Metarrhizium sp. f3. |
| PubMed:Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2. |
| PubMed:Synthetic analogues of TNP-470 and ovalicin reveal a common molecular basis for inhibition of angiogenesis and immunosuppression. |
| PubMed:The anti-angiogenic agent fumagillin covalently modifies a conserved active-site histidine in the Escherichia coli methionine aminopeptidase. |
| PubMed:Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. |
| PubMed:Chlovalicin, a new cytocidal antibiotic produced by Sporothrix sp. FO-4649. II. Physicochemical properties and structural elucidation. |
| PubMed:Chlovalicin, a new cytocidal antibiotic produced by Sporothrix sp. FO-4649. I. Taxonomy, fermentation, isolation and biological activities. |
| PubMed:The history of cyclosporin A (Sandimmune) revisited: another point of view. |
| PubMed:Enhanced toxicity of the immunosuppressant ovalicin upon application to the skin. |
| PubMed:On the mode of action of the immunosuppressive sesquiterpene ovalicin. |
| PubMed:On the mechanism of action of the cytostatic drug anguidine and of the immunosuppressive agent ovalicin, two sesquiterpenes from fungi. |
| PubMed:Application of deuterium magnetic resonance to biosynthetic studies. 1. Biosynthesis of ovalicin. |
| PubMed:Application of carbon-13 magnetic resonance to isoprenoid biosynthesis. II. Ovalicin and the use of doubly labeled mevalonate. |
| PubMed:Letter: Application of carbon-13 magnetic resonance to isoprenoid biosynthesis. I. Ovalicin. |
| PubMed:Immunosuppressive effects of ovalicin-semicarbazone. |
| PubMed:[Structure of ovalicin]. |
| PubMed:Effect of the immunosuppressive agent ovalicin on the kinetics of antibody formation. |
| PubMed:Immunosuppressive effect of a new antibiotic: ovalicin. |
| PubMed:Immunosuppressive and specific antimitotic effects of ovalicin. |
| PubMed:[Isolation and structure elucidation of ovalicin]. |
|
3D/inchi